Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma

Anouk E. J. Latenstein; Lydia G. M. van der Geest; Bert A. Bonsing; Bas Groot Koerkamp; Nadia Haj Mohammad; Ignace H. J. T. de Hingh; Vincent E. de Meijer; Izaak Q. Molenaar; Hjalmar C. van Santvoort; Geertjan van Tienhoven; Joanne Verheij; Pauline A. J. Vissers; Judith de Vos-Geelen; Olivier R. Busch; Casper H. J. van Eijck; Hanneke W. M. van Laarhoven; Marc G. Besselink; Johanna W. Wilmink; Dutch Pancreatic Canc Grp

doi:10.1016/j.ejca.2019.11.002

Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma

Anouk E. J. Latenstein^*, Lydia G. M. van der Geest, Bert A. Bonsing, Bas Groot Koerkamp, Nadia Haj Mohammad, Ignace H. J. T. de Hingh, Vincent E. de Meijer, Izaak Q. Molenaar, Hjalmar C. van Santvoort, Geertjan van Tienhoven, Joanne Verheij, Pauline A. J. Vissers, Judith de Vos-Geelen, Olivier R. Busch, Casper H. J. van Eijck, Hanneke W. M. van Laarhoven, Marc G. Besselink, Johanna W. Wilmink, Dutch Pancreatic Canc Grp

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: In recent years, new treatment options have become available for pancreatic ductal adenocarcinoma (PDAC) including 5-fluorouracil, leucovorin, irinotecan and oxaliplatin. The impact hereof has not been assessed in nationwide cohort studies. This population-based study aimed to investigate nationwide trends in incidence, treatment and survival of PDAC.

Materials and methods: Patients with PDAC (1997-2016) were included from the Netherlands Cancer Registry. Results were categorised by treatment and by period of diagnosis (1997-2000, 2001-2004, 2005-2008, 2009-2012 and 2013-2016). Kaplane-Meier survival analysis was used to calculate overall survival.

Results: In a national cohort of 36,453 patients with PDAC, the incidence increased from 12.1 (1997-2000) to 15.3 (2013-2016) per 100,000 (p <0.001), whereas median overall survival increased from 3.1 to 3.8 months (p <0.001). Over time, the resection rate doubled (8.3% -16.6%, p-trend

Conclusion: The incidence of PDAC increased in the past two decades. Resection rates and use of adjuvant or palliative chemotherapy increased with improved survival in these patients. In all patients with PDAC, however, the survival benefit of 3 weeks is negligible because the majority of patients only received supportive care. (C) 2019 The Authors. Published by Elsevier Ltd.

Original language	English
Pages (from-to)	83-93
Number of pages	11
Journal	European Journal of Cancer
Volume	125
DOIs	https://doi.org/10.1016/j.ejca.2019.11.002
Publication status	Published - Jan 2020

Keywords

BODY
CANCER SURGERY
CENTRALIZATION
CHEMOTHERAPY
Epidemiology
GEMCITABINE
IMPACT
Incidence
PANCREATICODUODENECTOMY
Pancreatic cancer
RESECTION
Survival
EPIDEMIOLOGY

Access to Document

10.1016/j.ejca.2019.11.002Licence: CC BY-NC-ND

Cite this

Latenstein, A. E. J., van der Geest, L. G. M., Bonsing, B. A., Koerkamp, B. G., Mohammad, N. H., de Hingh, I. H. J. T., de Meijer, V. E., Molenaar, I. Q., van Santvoort, H. C., van Tienhoven, G., Verheij, J., Vissers, P. A. J., de Vos-Geelen, J., Busch, O. R., van Eijck, C. H. J., van Laarhoven, H. W. M., Besselink, M. G., Wilmink, J. W., & Dutch Pancreatic Canc Grp (2020). Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. European Journal of Cancer, 125, 83-93. https://doi.org/10.1016/j.ejca.2019.11.002

@article{89a97861c4ff47199ebe1f7e4cb03458,

title = "Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma",

abstract = "Background: In recent years, new treatment options have become available for pancreatic ductal adenocarcinoma (PDAC) including 5-fluorouracil, leucovorin, irinotecan and oxaliplatin. The impact hereof has not been assessed in nationwide cohort studies. This population-based study aimed to investigate nationwide trends in incidence, treatment and survival of PDAC.Materials and methods: Patients with PDAC (1997-2016) were included from the Netherlands Cancer Registry. Results were categorised by treatment and by period of diagnosis (1997-2000, 2001-2004, 2005-2008, 2009-2012 and 2013-2016). Kaplane-Meier survival analysis was used to calculate overall survival.Results: In a national cohort of 36,453 patients with PDAC, the incidence increased from 12.1 (1997-2000) to 15.3 (2013-2016) per 100,000 (p <0.001), whereas median overall survival increased from 3.1 to 3.8 months (p <0.001). Over time, the resection rate doubled (8.3% -16.6%, p-trendConclusion: The incidence of PDAC increased in the past two decades. Resection rates and use of adjuvant or palliative chemotherapy increased with improved survival in these patients. In all patients with PDAC, however, the survival benefit of 3 weeks is negligible because the majority of patients only received supportive care. (C) 2019 The Authors. Published by Elsevier Ltd.",

keywords = "BODY, CANCER SURGERY, CENTRALIZATION, CHEMOTHERAPY, Epidemiology, GEMCITABINE, IMPACT, Incidence, PANCREATICODUODENECTOMY, Pancreatic cancer, RESECTION, Survival, EPIDEMIOLOGY",

author = "Latenstein, {Anouk E. J.} and {van der Geest}, {Lydia G. M.} and Bonsing, {Bert A.} and Koerkamp, {Bas Groot} and Mohammad, {Nadia Haj} and {de Hingh}, {Ignace H. J. T.} and {de Meijer}, {Vincent E.} and Molenaar, {Izaak Q.} and {van Santvoort}, {Hjalmar C.} and {van Tienhoven}, Geertjan and Joanne Verheij and Vissers, {Pauline A. J.} and {de Vos-Geelen}, Judith and Busch, {Olivier R.} and {van Eijck}, {Casper H. J.} and {van Laarhoven}, {Hanneke W. M.} and Besselink, {Marc G.} and Wilmink, {Johanna W.} and {Dutch Pancreatic Canc Grp}",

note = "Funding Information: The authors thank the registration team of the Netherlands Cancer Registry for their dedicated data collection. The Dutch Pancreatic Cancer Project, including the Netherlands Cancer Registry, received funding from the Dutch Cancer Society (KWF Kankerbestrijding; grant no. UVA2013-5842 ). Appendix A Funding Information: The authors thank the registration team of the Netherlands Cancer Registry for their dedicated data collection. The Dutch Pancreatic Cancer Project, including the Netherlands Cancer Registry, received funding from the Dutch Cancer Society (KWF Kankerbestrijding; grant no. UVA2013-5842). Publisher Copyright: {\textcopyright} 2019 The Authors",

year = "2020",

month = jan,

doi = "10.1016/j.ejca.2019.11.002",

language = "English",

volume = "125",

pages = "83--93",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "ELSEVIER SCI LTD",

}

Latenstein, AEJ, van der Geest, LGM, Bonsing, BA, Koerkamp, BG, Mohammad, NH, de Hingh, IHJT, de Meijer, VE, Molenaar, IQ, van Santvoort, HC, van Tienhoven, G, Verheij, J, Vissers, PAJ, de Vos-Geelen, J, Busch, OR, van Eijck, CHJ, van Laarhoven, HWM, Besselink, MG, Wilmink, JW & Dutch Pancreatic Canc Grp 2020, 'Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma', European Journal of Cancer, vol. 125, pp. 83-93. https://doi.org/10.1016/j.ejca.2019.11.002

TY - JOUR

T1 - Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma

AU - Latenstein, Anouk E. J.

AU - van der Geest, Lydia G. M.

AU - Bonsing, Bert A.

AU - Koerkamp, Bas Groot

AU - Mohammad, Nadia Haj

AU - de Hingh, Ignace H. J. T.

AU - de Meijer, Vincent E.

AU - Molenaar, Izaak Q.

AU - van Santvoort, Hjalmar C.

AU - van Tienhoven, Geertjan

AU - Verheij, Joanne

AU - Vissers, Pauline A. J.

AU - de Vos-Geelen, Judith

AU - Busch, Olivier R.

AU - van Eijck, Casper H. J.

AU - van Laarhoven, Hanneke W. M.

AU - Besselink, Marc G.

AU - Wilmink, Johanna W.

AU - Dutch Pancreatic Canc Grp

N1 - Funding Information: The authors thank the registration team of the Netherlands Cancer Registry for their dedicated data collection. The Dutch Pancreatic Cancer Project, including the Netherlands Cancer Registry, received funding from the Dutch Cancer Society (KWF Kankerbestrijding; grant no. UVA2013-5842 ). Appendix A Funding Information: The authors thank the registration team of the Netherlands Cancer Registry for their dedicated data collection. The Dutch Pancreatic Cancer Project, including the Netherlands Cancer Registry, received funding from the Dutch Cancer Society (KWF Kankerbestrijding; grant no. UVA2013-5842). Publisher Copyright: © 2019 The Authors

PY - 2020/1

Y1 - 2020/1

N2 - Background: In recent years, new treatment options have become available for pancreatic ductal adenocarcinoma (PDAC) including 5-fluorouracil, leucovorin, irinotecan and oxaliplatin. The impact hereof has not been assessed in nationwide cohort studies. This population-based study aimed to investigate nationwide trends in incidence, treatment and survival of PDAC.Materials and methods: Patients with PDAC (1997-2016) were included from the Netherlands Cancer Registry. Results were categorised by treatment and by period of diagnosis (1997-2000, 2001-2004, 2005-2008, 2009-2012 and 2013-2016). Kaplane-Meier survival analysis was used to calculate overall survival.Results: In a national cohort of 36,453 patients with PDAC, the incidence increased from 12.1 (1997-2000) to 15.3 (2013-2016) per 100,000 (p <0.001), whereas median overall survival increased from 3.1 to 3.8 months (p <0.001). Over time, the resection rate doubled (8.3% -16.6%, p-trendConclusion: The incidence of PDAC increased in the past two decades. Resection rates and use of adjuvant or palliative chemotherapy increased with improved survival in these patients. In all patients with PDAC, however, the survival benefit of 3 weeks is negligible because the majority of patients only received supportive care. (C) 2019 The Authors. Published by Elsevier Ltd.

AB - Background: In recent years, new treatment options have become available for pancreatic ductal adenocarcinoma (PDAC) including 5-fluorouracil, leucovorin, irinotecan and oxaliplatin. The impact hereof has not been assessed in nationwide cohort studies. This population-based study aimed to investigate nationwide trends in incidence, treatment and survival of PDAC.Materials and methods: Patients with PDAC (1997-2016) were included from the Netherlands Cancer Registry. Results were categorised by treatment and by period of diagnosis (1997-2000, 2001-2004, 2005-2008, 2009-2012 and 2013-2016). Kaplane-Meier survival analysis was used to calculate overall survival.Results: In a national cohort of 36,453 patients with PDAC, the incidence increased from 12.1 (1997-2000) to 15.3 (2013-2016) per 100,000 (p <0.001), whereas median overall survival increased from 3.1 to 3.8 months (p <0.001). Over time, the resection rate doubled (8.3% -16.6%, p-trendConclusion: The incidence of PDAC increased in the past two decades. Resection rates and use of adjuvant or palliative chemotherapy increased with improved survival in these patients. In all patients with PDAC, however, the survival benefit of 3 weeks is negligible because the majority of patients only received supportive care. (C) 2019 The Authors. Published by Elsevier Ltd.

KW - BODY

KW - CANCER SURGERY

KW - CENTRALIZATION

KW - CHEMOTHERAPY

KW - Epidemiology

KW - GEMCITABINE

KW - IMPACT

KW - Incidence

KW - PANCREATICODUODENECTOMY

KW - Pancreatic cancer

KW - RESECTION

KW - Survival

KW - EPIDEMIOLOGY

U2 - 10.1016/j.ejca.2019.11.002

DO - 10.1016/j.ejca.2019.11.002

M3 - Article

C2 - 31841792

SN - 0959-8049

VL - 125

SP - 83

EP - 93

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -